Identification of new biomarkers and therapeutic targets for MDR tumours - Stratagem
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment | Blood Cancer Journal
SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors - The Breast
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment - Abstract - Europe PMC
Correlation plots between the rate of change (RC) in the (%) inhibition... | Download Scientific Diagram
Cardiotoxicity Due to Proteasome Dysfunction | Bioimaging-GR, Virtual Laboratory
PARTNERS — Emotive - Storytelling for cultural heritage
Home
Ioannis Trougakos
Olive Bioactives: applications and prospects | LE STUDIUM
Ph.D. Ioannis P Trougakos - Research Lecturer - National Hellenic Research Foundation | LinkedIn
Molecular Mechanisms and Models of Aging, Volume 1119 (Annals of the New York Academy of Sciences): 9781573316866: Gonos, Efstathios S., Trougakos, Ioannis P., Chondrogianni, Niki: Books - Amazon.com
Clusterin overexpression in mice exacerbates diabetic phenotypes but suppresses tumor progression in a mouse melanoma model | Aging
Ph.D. Ioannis P Trougakos - Research Lecturer - National Hellenic Research Foundation | LinkedIn
PDF) Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors
Universal Design: A Step toward Successful Aging – topic of research paper in Psychology. Download scholarly article PDF and read for free on CyberLeninka open science hub.
University of Athens | Tascmar
Loop | Ioannis Trougakos
Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications | Journal of Biomedical Science | Full Text
Identification of new biomarkers and therapeutic targets for MDR tumours - Stratagem
Comparison of neutralizing antibody responses against SARS‐CoV‐2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier? - Terpos - 2021 -
The Speakers – ICSA 2019 Athens
Ioannis P. Trougakos's research works | National and Kapodistrian University of Athens, Athens (uoa) and other places
Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine | SpringerLink
